Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
Company profile
Ticker
OMCL
Exchange
Website
CEO
Mr. Randall A. Lipps
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
APOGEE ENTERPRISES INC
SEC CIK
Corporate docs
Subsidiaries
Omnicell Pty Ltd • Omnicell (Beijing) Technology Co. Ltd • Omnicell GmbH • Omnicell SAS • Omnicell S.r.l. • Omnicell India Private Limited • Omnicell B.V. • Omnicell Limited • Hub and Spoke Innovations Limited • ateb, Inc. ...
IRS number
943166458
OMCL stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer
25 Sep 24
10-Q
2024 Q2
Quarterly report
6 Aug 24
8-K
Omnicell Announces Second Quarter 2024 Results
1 Aug 24
S-8
Registration of securities for employees
21 Jun 24
8-K/A
Departure of Directors or Certain Officers
4 Jun 24
8-K
Departure of Directors or Certain Officers
24 May 24
SD
Conflict minerals disclosure
14 May 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Omnicell Announces First Quarter 2024 Results
2 May 24
ARS
2023 FY
Annual report to shareholders
11 Apr 24
Transcripts
OMCL
Earnings call transcript
2024 Q2
1 Aug 24
OMCL
Earnings call transcript
2024 Q1
2 May 24
OMCL
Earnings call transcript
2023 Q4
8 Feb 24
OMCL
Earnings call transcript
2023 Q3
2 Nov 23
OMCL
Earnings call transcript
2023 Q2
1 Aug 23
OMCL
Earnings call transcript
2023 Q2
1 Aug 23
OMCL
Earnings call transcript
2023 Q1
2 May 23
OMCL
Earnings call transcript
2022 Q4
28 Feb 23
OMCL
Earnings call transcript
2022 Q3
2 Nov 22
OMCL
Earnings call transcript
2022 Q2
7 Aug 22
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 578.24 mm | 578.24 mm | 578.24 mm | 578.24 mm | 578.24 mm | 578.24 mm |
Cash burn (monthly) | (no burn) | (no burn) | (no burn) | 2.47 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | n/a | 9.27 mm | n/a | n/a |
Cash remaining | n/a | n/a | n/a | 568.97 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | n/a | 230.4 | n/a | n/a |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 237 |
Opened positions | 34 |
Closed positions | 53 |
Increased positions | 91 |
Reduced positions | 84 |
13F shares | Current |
---|---|
Total value | 1.23 tn |
Total shares | 46.35 mm |
Total puts | 33.20 k |
Total calls | 153.20 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
BLK BlackRock | 8.18 mm | $221.56 bn |
Vanguard | 5.64 mm | $152.59 bn |
Cadian Capital Management | 2.47 mm | $66.98 bn |
STT State Street | 2.24 mm | $60.53 bn |
Pacer Advisors | 2.07 mm | $56.05 bn |
Champlain Investment Partners | 1.72 mm | $46.66 bn |
Dimensional Fund Advisors | 1.18 mm | $31.95 bn |
Geode Capital Management | 1.10 mm | $29.83 bn |
BK The Bank of New York Mellon Corporation | 1.09 mm | $29.49 bn |
D. E. Shaw & Co. | 1.09 mm | $29.45 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Sep 24 | Corey J Manley | Common Stock | Payment of exercise | Dispose F | No | No | 43.16 | 71 | 3.06 k | 49,449 |
15 Aug 24 | Corey J Manley | Common Stock | Payment of exercise | Dispose F | No | No | 42.93 | 1,354 | 58.13 k | 49,520 |
15 Aug 24 | Brian H. Nutt | Common Stock | Grant | Acquire A | No | No | 0 | 6,647 | 0.00 | 9,865 |
15 Aug 24 | Nchacha Etta | Common Stock | Payment of exercise | Dispose F | No | No | 42.93 | 2,830 | 121.49 k | 74,324 |
News
Wells Fargo Maintains Equal-Weight on Omnicell, Raises Price Target to $41
14 Oct 24
The Analyst Verdict: Omnicell In The Eyes Of 6 Experts
9 Oct 24
Benchmark Reiterates Buy on Omnicell, Maintains $48 Price Target
9 Oct 24
The Analyst Landscape: 5 Takes On Omnicell
23 Aug 24
JP Morgan Maintains Neutral on Omnicell, Raises Price Target to $37
23 Aug 24
Press releases
Omnicell to Release Third Quarter 2024 Financial Results on October 30, 2024
7 Oct 24
Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer
25 Sep 24
Omnicell Announces Central Med Automation Service
20 Aug 24
Omnicell to Present at the 2024 Wells Fargo Healthcare Conference
15 Aug 24
Omnicell Announces Second Quarter 2024 Results
1 Aug 24